SCHEMBL7609434

SCHEMBL7609434

CCCC(C(=O)O)c1c(NP(=O)(O)Cc2ccccc2)ccc2ccccc12

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
PSIP1 O75475 1/20 0.36
ACP3 P15309 2/20 0.35
ALDH1A1 P00352 1/20 0.35
PPARG P37231 2/20 0.34
PPARA Q07869 2/20 0.34
MMP1 P03956 1/20 0.34
GAA P10253 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
GPR55 Q9Y2T6 1/20 0.34
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
HPGD P15428 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7606879 0.94 CNR2 (0.36) MEN1KMT2AALDH1A1GAANPSR1
SCHEMBL7609447 0.91 ACP3 (0.36) MEN1KMT2AACP3ALDH1A1PPARG
SCHEMBL7607490 0.84 AKR1B1 (0.39) MEN1KMT2AACP3ALDH1A1GAA
SCHEMBL7605243 0.78 HTT (0.38) MEN1KMT2APSIP1ACP3ALDH1A1
SCHEMBL7604710 0.77 ALOX5 (0.38) MEN1KMT2APSIP1ALDH1A1MMP1
SCHEMBL7604642 0.74 KDM4E (0.51) MEN1KMT2AACP3ALDH1A1GAA
SCHEMBL7606184 0.73 ALDH1A1 (0.41) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL7614727 0.73 KMT2A (0.41) MEN1KMT2AALDH1A1GAAKDM4E
SCHEMBL7608438 0.72 CETP (0.39) ALDH1A1PPARGGAAHTTNPSR1
SCHEMBL7605170 0.71 CYP1A2 (0.41) MEN1KMT2AACP3ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2002514160-A 2002-05-14 JP claimed
JP-2002514184-A 2002-05-14 JP claimed
EP-1005348-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 2000-06-07 EP claimed
EP-0936914-A4 1999-08-25 EP claimed
EP-0936914-A1 HYDROXY-PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1999-08-25 EP claimed
WO-1998013046-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 1998-04-02 WO claimed
WO-1997048400-A1 HYDROXY-PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1997-12-24 WO claimed
EP-1044206-A1 PRODRUGS OF NAALADASE INHIBITORS Guildford Pharmaceuticals Inc. (US) 2000-10-18 EP disclosed
EP-1005348-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 2000-06-07 EP disclosed
US-6046180-A NAALADase inhibitors GUILFORD PHARMACEUTICALS INC. (US) 2000-04-04 US disclosed
WO-1999033849-A1 PRODRUGS OF NAALADASE INHIBITORS GUILDFORD PHARMACEUTICALS INC. (US) 1999-07-08 WO disclosed
WO-1998013046-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 1998-04-02 WO disclosed